Teva Denied On LAI Risperidone But Expected To Bounce Back ‘Quickly’

Israeli Firm ‘Reviewing Its Next Steps’ And Will ‘Work Closely’ With FDA

 
• By Dean Rudge
  
Hybrid
Teva and MedinCell are collaborating on a 505(b)(2) risperidone • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

More from Products